Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.470 -0.590 (-19.28%)

Streaming Delayed Price Updated: 2:53 PM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Volume	19,691,279
Open	3.030
Bid (Size)	2.470 (144,200)
Ask (Size)	2.480 (112,900)
Prev. Close	3.060
Today's Range	2.460 - 3.080
52wk Range	0.8621 - 4.460
Shares Outstanding	142,183,418
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

Today 8:02 EDT

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.

Via Benzinga

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

April 13, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+83.0%	+83.0%
1 Month	+1.2%	+1.2%
3 Month	+47.9%	+47.9%
6 Month	+94.5%	+94.5%
1 Year	+72.7%	+72.7%

More News

These stocks are making the most noise in today's session. ↗

April 13, 2026

Via Chartmill

ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology

April 13, 2026

Via AB Newswire

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts ↗

March 12, 2026

Via Chartmill

Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗

April 13, 2026

Via Benzinga

These stocks are gapping in today's session ↗

April 13, 2026

Via Chartmill

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗

April 13, 2026

Via Benzinga

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Via Chartmill

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

April 13, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Friday's after-hours session. ↗

April 10, 2026

Via Chartmill

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

April 10, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗

March 12, 2026

Via The Motley Fool

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

March 12, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

March 02, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

February 05, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗

January 21, 2026

Via The Motley Fool

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

January 12, 2026

From Equity Insider

Via GlobeNewswire

The market is filled with gapping stocks in Friday's session. ↗

January 09, 2026

Via Chartmill

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

January 08, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

Via The Motley Fool

What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗

December 26, 2025

Via The Motley Fool

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗

December 16, 2025

Via Benzinga

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

December 15, 2025

From Allogene Therapeutics, Inc.

Via GlobeNewswire

The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance

December 04, 2025

Via MarketMinute

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?

Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?

Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?

The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market

What is the current price of Allogene Therapeutics, Inc. - Common Stock?

The current price of Allogene Therapeutics, Inc. - Common Stock is 2.470

When was Allogene Therapeutics, Inc. - Common Stock last traded?

The last trade of Allogene Therapeutics, Inc. - Common Stock was at 04/14/26 02:53 PM ET

What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?

The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 351.19M

How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?

Allogene Therapeutics, Inc. - Common Stock has 351M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.